{"id":780965,"date":"2023-08-30T10:11:19","date_gmt":"2023-08-30T14:11:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/"},"modified":"2023-08-30T10:11:19","modified_gmt":"2023-08-30T14:11:19","slug":"paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/","title":{"rendered":"PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        \n      <\/p>\n<p align=\"center\">\n        <i>Presentation on Tuesday, September 12, 2023 at 3:00pm EDT<\/i>\n      <\/p>\n<p>TARRYTOWN, NY, Aug.  30, 2023  (GLOBE NEWSWIRE) &#8212; via <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_UvS6732mFV0BjLp3JjVs8-6XhbnXd8HQMffvO9cHI4unUE25UaUP_Vu2m-J_sIqDkTXHLDPvV0no2ic5R_IW4d3fzApHdMjI_d35WySm4A=\" rel=\"nofollow noopener\" target=\"_blank\">NewMediaWire<\/a> &#8212; PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced that it will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place September 11 \u2013 13, 2023, in New York, NY.<\/p>\n<p align=\"justify\">Howard Weisman, Chief Executive Officer, will present a corporate overview on Tuesday, September 12, 2023 at 3:00pm EDT at the Lotte New York Palace Hotel. In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. <\/p>\n<p align=\"justify\">A webcast of the event will be available on the Investor\u2019s section of the company\u2019s website at www.paxmedica.com. Following the event, a replay of the presentation will be available on the PaxMedica website for at least 90 days.<\/p>\n<p align=\"justify\">\n        <b>About PaxMedica<\/b>\n      <\/p>\n<p align=\"justify\">PaxMedica is a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (\u201cAPT\u201d) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including Autism Spectrum Disorder (\u201cASD\u201d), to Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome (\u201cME\/CFS\u201d), a debilitating physical and cognitive disorder. One of PaxMedica\u2019s primary points of focus is the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancing the clinical understanding of using that agent against other disorders such as ME\/CFS. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aflgdSgyz3jmbx5SDOfHKXTxRAQZdq1P5Iaj95cGcDxw6bo26MZgidod68ARDimAmKK90XTG_zcCdvhelUBGTH8TFsAjuh1rRNncOVeHZ_I=\" rel=\"nofollow noopener\" target=\"_blank\">www.paxmedica.com<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements.\u201d Forward-looking statements reflect our current view about future events. Investors can identify these forward-looking statements by words or phrases such as \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201caim,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cis\/are likely to,\u201d \u201cpropose,\u201d \u201cpotential,\u201d \u201ccontinue\u201d or similar expressions. These forward-looking statements include our anticipated clinical program, the timing and success of our anticipated data announcements, pre-clinical and clinical trials and regulatory filings, statements about the strength of our balance sheet. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company\u2019s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Such risks and uncertainties include, but are not limited to, risks associated with the Company\u2019s development work, including any delays or changes to the timing, cost and success of the Company\u2019s product development and clinical trials, risk of insufficient capital resources, cash funding and cash burn and risks associated with intellectual property and infringement claims.\u00a0 The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results described in the Company\u2019s \u201cRisk Factors\u201d section and other sections in its most recent Annual Report on Form 10-K, and subsequent quarterly and other filings with the U.S. Securities and Exchange Commission.<\/p>\n<p>\n        <b>Contacts <\/b>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WxKworsyOtcsK0LpVbFVKOO0fXVLLm32VKKWrVBYGLTwpZ-mA20oJVgRDoBrdTlRIJNthGsKeh9IeuJ4EwW3uzY-usCMW6CE6uBvumW1Uv_c2ecFo4pKE9d05ep7TvWCJx0N_xcaXcfZacVzNtuhZQsIVAidMZhc1MQhAJs5--YNkoYJtKRFuPDoFUfU41WeGKgmLJ6cIOSLcc0en92dSID2vSuRDZAZGcfUSSlIYfXEMOnR_xP_uQV1zPwYBPhmA5OxDBCfMrgncPRi9UQvig==\" rel=\"nofollow noopener\" target=\"_blank\">ir@paxmedica.com <\/a>\n      <\/p>\n<p>Stephanie Prince <br \/> PCG Advisory <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M7bqIHddoiYhw6hJ-IR3zBKr6ZL8h0f2IeTeGBsyu5bLnclUpMEiNLtnCaSJx4esXYYbdv3qAISvFYSMBa78accZpa43c9eukGeGOy1rWR4=\" rel=\"nofollow noopener\" target=\"_blank\">sprince@pcgadvisory.com<\/a>\u00a0 <br \/> (646) 863-6341 <\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzA5NCM1Nzg5MTg5IzUwMDA3NzQ3NA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NzA5YTZjMWEtY2FkYS00ZjhkLTg0NzItM2U1OGFiOWU4OTBlLTUwMDA3NzQ3NA==\/tiny\/PaxMedica-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Presentation on Tuesday, September 12, 2023 at 3:00pm EDT TARRYTOWN, NY, Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced that it will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place September 11 \u2013 13, 2023, in New York, NY. Howard Weisman, Chief Executive Officer, will present a corporate overview on Tuesday, September 12, 2023 at 3:00pm EDT at the Lotte New York Palace Hotel. In addition to the presentation, company management will be available &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-780965","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Presentation on Tuesday, September 12, 2023 at 3:00pm EDT TARRYTOWN, NY, Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced that it will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place September 11 \u2013 13, 2023, in New York, NY. Howard Weisman, Chief Executive Officer, will present a corporate overview on Tuesday, September 12, 2023 at 3:00pm EDT at the Lotte New York Palace Hotel. In addition to the presentation, company management will be available &hellip; Continue reading &quot;PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-30T14:11:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzA5NCM1Nzg5MTg5IzUwMDA3NzQ3NA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference\",\"datePublished\":\"2023-08-30T14:11:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/\"},\"wordCount\":593,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzA5NCM1Nzg5MTg5IzUwMDA3NzQ3NA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/\",\"name\":\"PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzA5NCM1Nzg5MTg5IzUwMDA3NzQ3NA==\",\"datePublished\":\"2023-08-30T14:11:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzA5NCM1Nzg5MTg5IzUwMDA3NzQ3NA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzA5NCM1Nzg5MTg5IzUwMDA3NzQ3NA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk","og_description":"Presentation on Tuesday, September 12, 2023 at 3:00pm EDT TARRYTOWN, NY, Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced that it will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place September 11 \u2013 13, 2023, in New York, NY. Howard Weisman, Chief Executive Officer, will present a corporate overview on Tuesday, September 12, 2023 at 3:00pm EDT at the Lotte New York Palace Hotel. In addition to the presentation, company management will be available &hellip; Continue reading \"PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-30T14:11:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzA5NCM1Nzg5MTg5IzUwMDA3NzQ3NA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference","datePublished":"2023-08-30T14:11:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/"},"wordCount":593,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzA5NCM1Nzg5MTg5IzUwMDA3NzQ3NA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/","name":"PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzA5NCM1Nzg5MTg5IzUwMDA3NzQ3NA==","datePublished":"2023-08-30T14:11:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzA5NCM1Nzg5MTg5IzUwMDA3NzQ3NA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzA5NCM1Nzg5MTg5IzUwMDA3NzQ3NA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paxmedica-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=780965"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780965\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=780965"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=780965"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=780965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}